Boston Scientific Acquires Penumbra for $14.5 Billion
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 15 2026
0mins
Should l Buy PEN?
Source: NASDAQ.COM
Penumbra Inc. shares surged by 12.25% as the stock reached a 52-week high following the announcement of its acquisition by Boston Scientific for $374 per share in a cash and stock deal valued at approximately $14.5 billion.
The acquisition allows Boston Scientific to expand into the mechanical thrombectomy and neurovascular markets, addressing the growing demand for vascular disease treatments. The deal is expected to be financed through a combination of cash and new debt, with initial earnings per share dilution anticipated, but a neutral to slightly accretive impact expected in the second year. This strategic move highlights Penumbra's strong market position and innovative product offerings in the healthcare sector.
This acquisition not only enhances Boston Scientific's competitive edge but also underscores Penumbra's significant role in the medical technology landscape, potentially leading to increased investor confidence and market performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PEN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PEN
Wall Street analysts forecast PEN stock price to rise
15 Analyst Rating
14 Buy
1 Hold
0 Sell
Strong Buy
Current: 344.390
Low
266.00
Averages
344.64
High
388.00
Current: 344.390
Low
266.00
Averages
344.64
High
388.00
About PEN
Penumbra, Inc. is a thrombectomy company, which is focused on developing technologies for challenging medical conditions, such as ischemic stroke, venous thromboembolism, such as pulmonary embolism, and acute limb ischemia. The Company's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. It focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investor Rights Law Firm Investigates Multiple Companies
- Potential Violation Investigation: Halper Sadeh LLC is investigating Penumbra, Inc. (NYSE:PEN) regarding its sale to Boston Scientific Corporation for either $374 in cash or 3.8721 shares of Boston Scientific common stock, raising concerns about shareholder rights.
- Shareholder Rights Protection: SunOpta Inc. (NASDAQ:STKL) is being sold to Refresco for $6.50 per share in cash, prompting Halper Sadeh LLC to remind shareholders to be aware of their rights and options to ensure transparency and fairness in the transaction.
- Merger Transaction Review: The merger between Brink's Company (NYSE:BCO) and NCR Atleos Corporation will result in Brink's shareholders owning approximately 78% of the combined entity, with Halper Sadeh LLC potentially seeking increased compensation for shareholders.
- Legal Support Services: LINKBANCORP, Inc. (NASDAQ:LNKB) is selling for 0.1350 shares of Burke & Herbert common stock per share, and Halper Sadeh LLC offers no-cost legal consultations to help shareholders understand their rights and possible legal remedies.
See More
Monteverde Law Firm Investigates Multiple Acquisition Cases
- Acquisition Investigations: Monteverde & Associates is investigating the transaction between Penumbra, Inc. and Boston Scientific Corporation, where shareholders are expected to receive either 3.8721 shares of Boston Scientific or $374 in cash per share, potentially impacting shareholder returns significantly.
- SunOpta Acquisition Details: In the deal with Pegasus BidCo B.V., SunOpta Inc. shareholders are expected to receive $6.50 per share in cash, providing a direct cash return that enhances the investment value for shareholders.
- LINKBANCORP Transaction Structure: LINKBANCORP, Inc. shareholders will receive 0.1350 shares of Burke & Herbert common stock in their transaction, which is expected to affect the shareholder structure and future earnings potential.
- Merger Disclosure: Vine Hill Capital Investment Corp. shareholders will receive shares of the newly combined company in its merger with CoinShares International Limited, which may present new growth opportunities for shareholders.
See More
Penumbra Reports Significant Q4 Profit Growth
- Profit Growth: Penumbra Inc. reported a fourth-quarter profit of $47.34 million, translating to $1.20 per share, which marks a significant increase from last year's $33.68 million and $0.86 per share, indicating enhanced profitability.
- Adjusted Earnings: Excluding items, the company reported adjusted earnings of $46.51 million or $1.18 per share, reflecting ongoing growth and stability in its core business operations.
- Revenue Increase: The company's revenue rose by 22.1% to $385.38 million compared to $315.51 million last year, showcasing strong market demand and sales performance.
- Market Positioning: With substantial improvements in both profit and revenue, Penumbra strengthens its competitive position in the medical device industry, likely attracting increased investor interest in its future growth potential.
See More
Penumbra Reports Strong 2025 Financial Results
- Significant Revenue Growth: Total revenue for Q4 2025 reached $385.4 million, a 22.1% increase from Q4 2024, with the U.S. market contributing 77.6%, indicating strong domestic performance.
- Strong Product Sales: Sales of global thrombectomy products amounted to $254.7 million, up 15.7%, primarily driven by a 12.4% increase in the U.S. market, reflecting sustained demand in key product lines.
- Improved Gross Margin: The gross margin for Q4 2025 was 68.0%, up from 66.8% in Q4 2024, attributed to product mix optimization and enhanced production efficiency, signaling potential future profitability improvements.
- Controlled Operating Expenses: Although R&D expenses slightly increased to $21.8 million, total operating expenses as a percentage of revenue decreased to 52.6%, demonstrating the company's ability to effectively manage costs during expansion.
See More
Panoro Energy's Acquisition Significantly Expands Operations
- Acquisition Expansion: Panoro Energy ASA announced the acquisition of a 40.375% stake in Block G offshore Equatorial Guinea for $180 million, expected to double the company's size overnight, increasing production by approximately 80% and reserves by over 100%, thereby significantly enhancing cash flow and shareholder returns.
- Successful Fundraising: The company successfully closed an equity private placement raising just below $50 million, which was oversubscribed, indicating strong investor confidence, while also planning to utilize $150 million in headroom from its existing bond framework to support the acquisition.
- Strong Financial Position: As of December 31, 2025, Panoro reported a cash position of $77 million and cash flow from operations of $73 million, despite a revenue decline to $216 million in 2025, the company maintains positive cash flow, demonstrating financial resilience.
- Future Production Guidance: The production guidance for 2026 is set at 15,000 to 17,000 barrels per day, with expectations of remaining cash flow positive even at $60 per barrel, and potential cash flow reaching $800 million to $900 million at $75 to $80 per barrel, further supporting the company's long-term growth strategy.
See More
US Supreme Court Strikes Down Trump's Tariff Regime
- Market Reaction: The US Supreme Court's 6-3 ruling against Trump's tariff regime led to a swift market rebound, with the S&P 500 rising 0.7%, indicating a moderate investor optimism regarding the policy shift despite initial losses.
- Limited Economic Impact: The ruling affects approximately 60% of tariffs under the IEEPA, and while it could lead to refund requests totaling up to $175 billion, the overall economic impact is deemed limited, resulting in a muted market response.
- Oil Price Fluctuations: Oil prices surged about 5.5% over the past week due to escalating tensions in the Middle East, with projections suggesting a potential increase of $10 to $15 per barrel if the US engages in military action, highlighting the significant geopolitical risks to energy markets.
- Upcoming Economic Data: The forthcoming Producer Price Index (PPI) will provide investors with crucial insights into inflation trends, which are expected to influence the Federal Reserve's monetary policy, particularly as inflation remains persistently above target levels.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Potential Violation Investigation: Halper Sadeh LLC is investigating Penumbra, Inc. (NYSE:PEN) regarding its sale to Boston Scientific Corporation for either $374 in cash or 3.8721 shares of Boston Scientific common stock, raising concerns about shareholder rights.
- Shareholder Rights Protection: SunOpta Inc. (NASDAQ:STKL) is being sold to Refresco for $6.50 per share in cash, prompting Halper Sadeh LLC to remind shareholders to be aware of their rights and options to ensure transparency and fairness in the transaction.
- Merger Transaction Review: The merger between Brink's Company (NYSE:BCO) and NCR Atleos Corporation will result in Brink's shareholders owning approximately 78% of the combined entity, with Halper Sadeh LLC potentially seeking increased compensation for shareholders.
- Legal Support Services: LINKBANCORP, Inc. (NASDAQ:LNKB) is selling for 0.1350 shares of Burke & Herbert common stock per share, and Halper Sadeh LLC offers no-cost legal consultations to help shareholders understand their rights and possible legal remedies.
See More
Monteverde Law Firm Investigates Multiple Acquisition Cases
- Acquisition Investigations: Monteverde & Associates is investigating the transaction between Penumbra, Inc. and Boston Scientific Corporation, where shareholders are expected to receive either 3.8721 shares of Boston Scientific or $374 in cash per share, potentially impacting shareholder returns significantly.
- SunOpta Acquisition Details: In the deal with Pegasus BidCo B.V., SunOpta Inc. shareholders are expected to receive $6.50 per share in cash, providing a direct cash return that enhances the investment value for shareholders.
- LINKBANCORP Transaction Structure: LINKBANCORP, Inc. shareholders will receive 0.1350 shares of Burke & Herbert common stock in their transaction, which is expected to affect the shareholder structure and future earnings potential.
- Merger Disclosure: Vine Hill Capital Investment Corp. shareholders will receive shares of the newly combined company in its merger with CoinShares International Limited, which may present new growth opportunities for shareholders.
See More
Penumbra Reports Significant Q4 Profit Growth
- Profit Growth: Penumbra Inc. reported a fourth-quarter profit of $47.34 million, translating to $1.20 per share, which marks a significant increase from last year's $33.68 million and $0.86 per share, indicating enhanced profitability.
- Adjusted Earnings: Excluding items, the company reported adjusted earnings of $46.51 million or $1.18 per share, reflecting ongoing growth and stability in its core business operations.
- Revenue Increase: The company's revenue rose by 22.1% to $385.38 million compared to $315.51 million last year, showcasing strong market demand and sales performance.
- Market Positioning: With substantial improvements in both profit and revenue, Penumbra strengthens its competitive position in the medical device industry, likely attracting increased investor interest in its future growth potential.
See More
Penumbra Reports Strong 2025 Financial Results
- Significant Revenue Growth: Total revenue for Q4 2025 reached $385.4 million, a 22.1% increase from Q4 2024, with the U.S. market contributing 77.6%, indicating strong domestic performance.
- Strong Product Sales: Sales of global thrombectomy products amounted to $254.7 million, up 15.7%, primarily driven by a 12.4% increase in the U.S. market, reflecting sustained demand in key product lines.
- Improved Gross Margin: The gross margin for Q4 2025 was 68.0%, up from 66.8% in Q4 2024, attributed to product mix optimization and enhanced production efficiency, signaling potential future profitability improvements.
- Controlled Operating Expenses: Although R&D expenses slightly increased to $21.8 million, total operating expenses as a percentage of revenue decreased to 52.6%, demonstrating the company's ability to effectively manage costs during expansion.
See More
Panoro Energy's Acquisition Significantly Expands Operations
- Acquisition Expansion: Panoro Energy ASA announced the acquisition of a 40.375% stake in Block G offshore Equatorial Guinea for $180 million, expected to double the company's size overnight, increasing production by approximately 80% and reserves by over 100%, thereby significantly enhancing cash flow and shareholder returns.
- Successful Fundraising: The company successfully closed an equity private placement raising just below $50 million, which was oversubscribed, indicating strong investor confidence, while also planning to utilize $150 million in headroom from its existing bond framework to support the acquisition.
- Strong Financial Position: As of December 31, 2025, Panoro reported a cash position of $77 million and cash flow from operations of $73 million, despite a revenue decline to $216 million in 2025, the company maintains positive cash flow, demonstrating financial resilience.
- Future Production Guidance: The production guidance for 2026 is set at 15,000 to 17,000 barrels per day, with expectations of remaining cash flow positive even at $60 per barrel, and potential cash flow reaching $800 million to $900 million at $75 to $80 per barrel, further supporting the company's long-term growth strategy.
See More
US Supreme Court Strikes Down Trump's Tariff Regime
- Market Reaction: The US Supreme Court's 6-3 ruling against Trump's tariff regime led to a swift market rebound, with the S&P 500 rising 0.7%, indicating a moderate investor optimism regarding the policy shift despite initial losses.
- Limited Economic Impact: The ruling affects approximately 60% of tariffs under the IEEPA, and while it could lead to refund requests totaling up to $175 billion, the overall economic impact is deemed limited, resulting in a muted market response.
- Oil Price Fluctuations: Oil prices surged about 5.5% over the past week due to escalating tensions in the Middle East, with projections suggesting a potential increase of $10 to $15 per barrel if the US engages in military action, highlighting the significant geopolitical risks to energy markets.
- Upcoming Economic Data: The forthcoming Producer Price Index (PPI) will provide investors with crucial insights into inflation trends, which are expected to influence the Federal Reserve's monetary policy, particularly as inflation remains persistently above target levels.
See More
